Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 1;42(8):1331-1339.
doi: 10.1097/HJH.0000000000003726. Epub 2024 Mar 28.

Multiple urinary peptides are associated with hypertension: a link to molecular pathophysiology

Emmanouil Mavrogeorgis  1   2 , Margarita Kondyli  3 , Harald Mischak  1 , Antonia Vlahou  4 , Justyna Siwy  1 , Peter Rossing  5   6 , Archie Campbell  7 , Carina M C Mels  8   9 , Christian Delles  10 , Jan A Staessen  11 , Agnieszka Latosinska  1 , Alexandre Persu  12   13
Affiliations

Multiple urinary peptides are associated with hypertension: a link to molecular pathophysiology

Emmanouil Mavrogeorgis et al. J Hypertens. .

Abstract

Objectives: Hypertension is a common condition worldwide; however, its underlying mechanisms remain largely unknown. This study aimed to identify urinary peptides associated with hypertension to further explore the relevant molecular pathophysiology.

Methods: Peptidome data from 2876 individuals without end-organ damage were retrieved from the Human Urinary Proteome Database, belonging to general population (discovery) or type 2 diabetic (validation) cohorts. Participants were divided based on systolic blood pressure (SBP) and diastolic BP (DBP) into hypertensive (SBP ≥140 mmHg and/or DBP ≥90 mmHg) and normotensive (SBP <120 mmHg and DBP <80 mmHg, without antihypertensive treatment) groups. Differences in peptide abundance between the two groups were confirmed using an external cohort ( n = 420) of participants without end-organ damage, matched for age, BMI, eGFR, sex, and the presence of diabetes. Furthermore, the association of the peptides with BP as a continuous variable was investigated. The findings were compared with peptide biomarkers of chronic diseases and bioinformatic analyses were conducted to highlight the underlying molecular mechanisms.

Results: Between hypertensive and normotensive individuals, 96 (mostly COL1A1 and COL3A1) peptides were found to be significantly different in both the discovery (adjusted) and validation (nominal significance) cohorts, with consistent regulation. Of these, 83 were consistently regulated in the matched cohort. A weak, yet significant, association between their abundance and standardized BP was also observed.

Conclusion: Hypertension is associated with an altered urinary peptide profile with evident differential regulation of collagen-derived peptides. Peptides related to vascular calcification and sodium regulation were also affected. Whether these modifications reflect the pathophysiology of hypertension and/or early subclinical organ damage requires further investigation.

PubMed Disclaimer

References

    1. Latosinska A, Siwy J, Mischak H, Frantzi M. Peptidomics and proteomics based on CE-MS as a robust tool in clinical application: the past, the present, and the future. Electrophoresis 2019; 40:2294–2308.
    1. Catanese L, Siwy J, Mischak H, Wendt R, Beige J, Rupprecht H. Recent advances in urinary peptide and proteomic biomarkers in chronic kidney disease: a systematic review. Int J Mol Sci 2023; 24:9156.
    1. He T, Mischak M, Clark AL, Campbell RT, Delles C, Díez J, et al. Urinary peptides in heart failure: a link to molecular pathophysiology. Eur J Heart Fail 2021; 23:1875–1887.
    1. Mavrogeorgis E, He T, Mischak H, Latosinska A, Vlahou A, Schanstra JP, et al. Urinary peptidomic liquid biopsy for noninvasive differential diagnosis of chronic kidney disease. Nephrol Dial Transplant 2024; 39:453–462.
    1. Jaimes Campos MA, Andújar I, Keller F, Mayer G, Rossing P, Staessen JA, et al. Prognosis and personalized in silico prediction of treatment efficacy in cardiovascular and chronic kidney disease: a proof-of-concept study. Pharmaceuticals (Basel) 2023; 16:1298.